|
Real-time Estimate
Cboe BZX
19:42:20 02/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 25.85 USD | +0.15% |
|
-2.53% | +12.04% |
| 09-02 | Ultragenyx Pharmaceutical Inc. Publishes 96-Week Phase 3 Data For GENGLYCOS AAV Gene Therapy In GSDIa | CI |
| 08-20 | Ultragenyx Pharmaceutical Inc. - Special Call |
| Market Cap | 2.54B 2.19B 2.06B 1.88B 3.51B 240B 3.54B 24.41B 9.47B 123B 9.53B 9.32B 402B | P/E 2026 * |
-6.56x | P/E 2027 * | -35.8x |
|---|---|---|---|---|---|
| Enterprise Value | 2.11B 1.82B 1.71B 1.56B 2.92B 199B 2.94B 20.29B 7.87B 102B 7.92B 7.74B 335B | EV / Sales 2026 * |
2.76x | EV / Sales 2027 * | 2.09x |
| Free-Float |
96.27% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Ultragenyx Pharmaceutical Inc.
| 1 day | +0.35% | ||
| 1 week | -2.53% | ||
| Current month | +2.22% | ||
| 1 month | +3.00% | ||
| 3 months | +18.32% | ||
| 6 months | +11.95% | ||
| Current year | +12.04% |
| 1 week | 24.73 |  | 26.8 |
| 1 month | 24.01 | | 28.5 |
| Current year | 18.29 | | 36.57 |
| 1 year | 18.29 | | 39.89 |
| 3 years | 18.29 | | 60.37 |
| 5 years | 18.29 | | 104.38 |
| 10 years | 18.29 | | 179.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
CEO | Chief Executive Officer | 65 | 22/04/2010 |
Howard Horn
DFI | Director of Finance/CFO | 49 | 16/10/2023 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/05/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
BRD | Director/Board Member | 65 | 22/04/2010 |
Matthew Fust
BRD | Director/Board Member | 62 | 01/01/2014 |
Michael Narachi
BRD | Director/Board Member | 66 | 20/02/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/3/26 A | Sell | General Counsel | -1,900 | 0.0019% | ||
| 8/3/26 A | Sell | Chief Financial Officer | -4,696 | 0.0048% | ||
| 7/1/26 A | Sell | Chief Financial Officer | -4,698 | 0.0048% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.15% | -2.53% | -19.54% | -32.24% | 2.54B | |
| +6.19% | +16.70% | +25.06% | -81.16% | 2.25B | |
| -0.73% | -1.04% | -13.52% | -6.93% | 353M | |
| -0.44% | +1.56% | -43.49% | - | 53.39M | |
| Average | +1.34% | +3.10% | -12.88% | -40.11% | 1.3B | |
| Weighted average by Cap. | +2.79% | +4.36% | -0.04% | -51.93% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 763M 658M 620M 565M 1.06B 72.04B 1.06B 7.34B 2.85B 36.83B 2.86B 2.8B 121B | 1.01B 871M 820M 747M 1.4B 95.34B 1.41B 9.71B 3.77B 48.74B 3.79B 3.71B 160B |
| Net income | -433M -374M -352M -321M -599M -40.91B -604M -4.17B -1.62B -20.92B -1.63B -1.59B -68.71B | -88.66M -76.49M -72.05M -65.65M -123M -8.38B -124M -853M -331M -4.28B -333M -326M -14.07B |
| Net Debt | -428M -370M -348M -317M -593M -40.46B -597M -4.12B -1.6B -20.69B -1.61B -1.57B -67.95B | -431M -372M -351M -319M -597M -40.76B -602M -4.15B -1.61B -20.84B -1.62B -1.58B -68.45B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/09/26 | $25.78 | -0.12% | 525,874 |
| 01/09/26 | $25.81 | +2.38% | 1,872,066 |
| 31/08/26 | $25.21 | -1.56% | 1,934,100 |
| 28/08/26 | $25.61 | -2.48% | 1,612,887 |
| 27/08/26 | $26.26 | -0.68% | 1,142,858 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RARE Stock
Select your edition
All financial news and data tailored to specific country editions
